19.04.24 | Vollzeit | Krailling | Bavarian Nordic GmbHRelated documents (Change Requests, Deviation Reports) Development of new QC assays Equipment qualifications Succeeding with our vision of becoming one of the largest pure-play vaccine companies in the world is an ambitious goal, and that is why we need people like you who are determined to make it happen
Später ansehen19.04.24 | Vollzeit | Krailling | Bavarian Nordic GmbHRelated documents (Change Requests, Deviation Reports) Development of new QC assays Equipment qualifications Succeeding with our vision of becoming one of the largest pure-play vaccine companies in the world is an ambitious goal, and that is why we need people like you who are determined to make it happen
Später ansehen19.04.24 | Vollzeit | Krailling | Bavarian Nordic GmbHRelated documents (Change Requests, Deviation Reports) Development of new QC assays Equipment qualifications Succeeding with our vision of becoming one of the largest pure-play vaccine companies in the world is an ambitious goal, and that is why we need people like you who are determined to make it happen
Später ansehen08.04.24 | Vollzeit | Krailling | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Krailling | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen08.04.24 | Vollzeit | Krailling | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehenVerpassen Sie nie wieder einen passenden Job!
Alle Jobs für Developer Design in Krailling kostenlos abonnieren.